Performance at Month End

Merrill Lynch UK Inv Tst PLC 15 May 2002 MONTHLY PERFORMANCE MERRILL LYNCH UK INVESTMENT TRUST plc All information is at 30 April 2002 and unaudited. Performance at month end with net income reinvested One Three One Three Five month months year years years Net asset value -3.6% -0.5% -20.8% -27.6% 7.7% Share price -3.7% -5.7% -26.1% -34.8% -2.0% FTSE All-Share Index -1.6% 1.7% -10.1% -10.8% 33.7% Sources: Merrill Lynch Investment Managers, Standard & Poor's Micropal At month end Net asset value* 878.97p Share price: 745.00p Discount: 15.2% Total assets: £156.8m Net Yield: 4.0% Gearing: 33.7% Effective gearing: 17.7% Value of debt: £39.5m Ordinary shares in issue: 13,493,799 *Includes current year net revenue of 10.14p. UK Sectors % Total Assets Financials 26.4 Non-Cyclical Consumer Goods 16.9 Cyclical Services 16.3 Resources 12.4 Non-Cyclical Services 8.2 Basic Industries 2.4 General Industrials 2.3 Information Technology 1.8 Utilities 1.3 Cash 12.8 Net current liabilities (0.8) Total 100.0 Ten Largest Equity Investments Company % Investments BP Amoco 8.8 Barclays 5.5 HSBC 5.3 HBOS 5.2 AstraZeneca 5.2 GlaxoSmithKline 5.2 Royal Bank of Scotland 4.6 Vodafone 4.5 Diageo 3.6 Amersham 3.2 Total 51.1 Market commentary UK Stockmarket Review UK equities retreated over the period, with the All-Share Index down 1.6%. The UK stockmarket received little help from US markets, as strong US GDP data was overshadowed by weakening industrial confidence and poor corporate newsflow. Domestic economic data provided little excitement - GDP in the first quarter rose only 0.1% quarter on quarter. At the sector level, Telecoms shares weighed greatest on the market, with Mobile shares being sold as investors continued to question the growth dynamics and profitability of the industry. As concerns over the health of the global economic recovery and corporate profitability resurfaced, defensives outperformed the more economically sensitive sectors. Fund Performance Review The Company's Net Asset Value (NAV) fell 3.6% during April, underperforming the FTSE All Share Index, which fell 1.6%. We suffered from our overweight position in mmO2, which fell as UK Telecoms shares were hit by profit warnings from their US counterparts. Our choice of shares in Pharmaceuticals was also negative, as Amersham and AstraZeneca both disappointed. Amersham fell after first quarter sales were dragged down by evidence of one-off pricing pressure in the Japanese diagnostics market, while AstraZeneca was forced by US regulators to delay the launch of Crestor, a key cholesterol lowering drug. These events were offset by strong performance in Financials, where our holdings in Barclays and HBOS performed strongly. Our avoidance of selected cyclical shares including Cable & Wireless and WPP was also beneficial, as investors favoured defensive issues. Outlook Recent weak headline growth belies starkly divergent trends within the UK economy. A strong service sector remains underpinned by low interest rates and a buoyant housing market. This contrasts with a very weak manufacturing sector. Interest rates are very low even for this stage in the cycle, and while the broader inflation numbers are subdued, service sector inflation appears to be more problematic. This implies that the Bank of England will respond quickly to signs of recovery in the economy. Whilst some sectoral themes may emerge, we intend to maintain our focus on strong stock ideas where we believe the stockmarket has underestimated a company's prospects. Latest information is available by typing www.mlim.co.uk/its on the internet, 'MLIMINDEX' on Reuters, 'MLIM' on Bloomberg or '8800' on Topic 3 (ICV terminal). 15 May 2002 This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings